Trial Profile
Optimisation of Primary HIV1 Infection Treatment (ANRS 147 OPTIPRIM)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs Maraviroc (Primary) ; Raltegravir (Primary) ; Darunavir; Emtricitabine/tenofovir disoproxil fumarate; Ritonavir
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms OPTIPRIM
- 22 Jan 2018 Results of estimation of residual drug concentrations (Ctrough) and exposures (AUC) by using published pharmacokinetic models published in the Journal of Antimicrobial Chemotherapy
- 26 Jul 2017 Results of pharmacokinetic substudy presented at the 9th International AIDS Society Conference on HIV Science
- 04 Feb 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.